Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study - A noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany

摘要: . Purpose:  To evaluate effectiveness, tolerability and safety of repeated intravitreal injections 0.5 mg ranibizumab for the treatment neovascular age-related macular degeneration in routine medical practice Germany. Methods:  A noninterventional study with 3470 patients treated 274 centres according to German guidelines, monthly during upload (3 months) followed by a maintenance phase (9 months) reinjections if medically indicated. Results:  Mean injection rate was 4.34 (SE = 0.05; median = 3.0). Best-corrected visual acuity (BCVA) remained stable (mean change 0.02 LogMAR, SE = 0.01, p = 0.0169) central retinal thickness (CRT) decreased (by −78.9 μm, SE = 2.95 μm, p < 0.0001). The NEI-VFQ 25 summary score showed positive stabilization mean 0.73 (SE = 0.37, p = 0.0501) compared baseline. Adverse events were documented 6.5% 3.9% these being classified as serious. Conclusions:  number administered over first year very low but still achieved BCVA, reduction CRT maintained vision-related quality life. management AMD Germany needs be improved achieve better results.